Anti-TNF therapy, which limits TNFR signaling, has been tested in mouse models for different inflammatory diseases, such as rheumatoid arthritis, psoriasis, and bowel diseases (99–101). This evidence concerns the gene TNFRSF1A and rheumatoid arthritis.